MarketPulse

thrombocytopenia

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Neumega Poised for Robust Growth Through 2030 as Oncology Demand Surges

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.
PFEpersonalized medicineAsia Pacific growth
GlobeNewswire Inc.GlobeNewswire Inc.··Macrogenics, Inc.

MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody